Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03226743
Other study ID # 01GY1602
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date July 12, 2018
Est. completion date October 7, 2022

Study information

Verified date November 2022
Source Universitätsklinikum Hamburg-Eppendorf
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aims of COMET are the implementation and evaluation of effectiveness and cost-effectiveness as well as processes of a collaborative and stepped care model for depressive, anxiety, somatoform and/or alcohol abuse disorders within a multiprofessional network in comparison to routine care. In a cluster-randomized controlled effectiveness trial 570 patients will be recruited by 38 general practitioner practices and followed with a prospective survey at four time points. The primary outcome is the change in health-related quality of life from baseline to 6-months follow-up. Secondary outcomes include disorder-specific symptom burden, response, remission, functional quality of life, cost-effectiveness, evaluation of processes and other clinical and psychosocial variables.


Description:

Aims are a) the implementation and outcome evaluation, b) the process evaluation, and c) the analysis of the cost-effectiveness of an innovative collaborative and stepped care model for patients with depressive, anxiety, somatoform and/or alcohol abuse disorders. Its novelty is the integration of these four disorders into one model. This approach is based on a) the high comorbidity between these disorders, b) the fact that they share a common etiological and diag-nostic basis, c) that similar evidence-based treatment options exist for them (e.g., self-help and psychoeducation, psychotherapy, pharmacotherapy), and d) that health care providers need to manage them together very often. The conceptual basis follows the principles of evidence-based medicine with a specific focus on guideline implementation and the principles of patient-centered care including access, coordination and continuity of care, patient information, patient involvement and empowerment. Based on a multi-professional cooperation of health care providers across different care sectors an integrated health care network consisting of general practitioners (GPs), mental health specialists (psychiatrists, psychotherapists) and inpatient facilities will be established. Evidence-based clinical practice guidelines and pathways of care with treatment options of varying intensity form the clinical and procedural basis of the network, including low-intensity treatments and e-mental health technologies. The study is planned as a randomized controlled effectiveness trial of a consecutive sample of patients with depressive and/or anxiety and/or somatoform and/or alcohol abuse disorders drawn from primary care (GP practices) and followed with a prospective survey at four time points. The study is intended to recruit a total of 570 patients from 38 GP practices. A cluster-randomization at the level of participating GP practices divides GPs into the intervention group, where patients are treated within a multi-professional collaborative and stepped care approach (including low-intensity treatments, direct access to mental health specialists, inpatient care etc., COMET), and the control group, where patients receive standard care (treatment as usual, TAU). Data collection is carried out with questionnaires as well as telephone interviews at four time-standardized measurement points within one year (baseline, 3, 6, 12 and 24 months). Additionally, independent research assistants perform standardized diagnostic interviews (CIDI) with patients at baseline to allow an assessment of diagnostic validity. The main research hypothesis is that the COMET model is more effective than TAU. Primary outcome is the change in health-related quality of life measured by the SF-36 mental health score from baseline to 6-months follow-up. Secondary outcomes include symptom burden of depressive, generalized anxiety, panic, somatoform and alcohol abuse syndromes (PHQ-9; GAD-7; PHQ-15; PHQ panic and alcohol abuse syndrome module; SSD-12), disorder-specific response and remission, functional quality of life (EQ-5D-5L), duration of untreated illness, and other clinical and psychosocial variables (outcome evaluation, Work Package 1). Furthermore, direct and indirect costs and the incremental cost-effectiveness ratio will be assessed (economic evaluation, Work Package 2). Finally, feasibility and acceptance of the COMET model as well as of the different treatment components are assessed, including the implementation process (process evaluation, Work Package 3). To this end, semi-structured interviews will be conducted at two measurement points, supplemented by standardized surveys among involved patients and providers.


Recruitment information / eligibility

Status Completed
Enrollment 615
Est. completion date October 7, 2022
Est. primary completion date April 12, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Inclusion criteria are a minimum age of 18, informed consent and one or more of the following positive ICD-10-diagnoses: depressive episode (F32), recurrent depressive disorder (F33), dysthymia (F34.1), agoraphobia (F40.0), social phobia (F40.1), panic disorder (F41.0), generalized anxiety disorder (F41.1), mixed anxiety and depressive disorder (F41.2), somatoform disorders (F45), and/or mental and behavioral disorders due to use of alcohol (F10.1, F.10.2) Exclusion Criteria: - Patients with insufficient knowledge of the German language, an acute psychosis or a health situation that does not allow questionnaire completion or patients already receiving current in- or outpatient psychiatric or psychotherapeutic care are excluded.

Study Design


Intervention

Other:
collaborative and stepped care model
Including elements: collaborative and stepped care of patients with mental disorders treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities initial training of participating health care providers formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders formalized ICD-diagnostics guideline-oriented treatment recommendations bibliotherapy or internet-based self-help for patient with mild to moderate disorders online referral platform case management for patients with severe disorders systematic and regular monitoring regular quality circles for participating health care providers

Locations

Country Name City State
Germany University Medical Center Hamburg Hamburg

Sponsors (3)

Lead Sponsor Collaborator
Universitätsklinikum Hamburg-Eppendorf Center for Health Care Research Hamburg, Hamburg Center for Health Economics

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary change in health-related quality of life measured with the Short Form Health Survey SF-36 mental health score from baseline to 6 months and 12 and 24 months after baseline
Secondary change in disorder-specific symptoms: depression measured on the major depressive module of the Patient Health Questionnaire PHQ: PHQ-9 from baseline to 6 months and 12 and 24 months after baseline
Secondary change in disorder-specific symptoms: panic measured on the panic module of the Patient Health Questionnaire PHQ: PHQ-panic module from baseline to 6 months and 12 and 24 months after baseline
Secondary change in disorder-specific symptoms: generalized anxiety measured on the generalized anxiety module of the Patient Health Questionnaire PHQ: GAD-7 from baseline to 6 months and 12 months and 24 months after baseline
Secondary change in disorder-specific symptoms: somatoform syndrome PHQ measured on the somatoform module of the Patient Health Questionnaire PHQ: PHQ-15 from baseline to 6 months and 12 and 24 months after baseline
Secondary change in disorder-specific symptoms: somatoform syndrome SSD-12 measured on the Somatic Symptom Disorder-B SSD-12 from baseline to 6 months and 12 and 24 months after baseline
Secondary change in disorder-specific symptoms: alcohol abuse disorder measured on the Alcohol Use Disorders Identification Test: AUDIT from baseline to 6 months and 12 and 24 months after baseline
Secondary cost effectiveness: direct costs will be assessed based on health care utilization, reduced productivity at work and work loss days measured by a modified version the Client Sociodemographic and Service Receipt Inventory (CSSRI). For the monetary valuation of resources, unit costs will be applied. from baseline to 6 months and 12 and 24 months after baseline
Secondary cost effectiveness: indirect costs will be assessed based on health care utilization, reduced productivity at work and work loss days measured by a modified version the Client Sociodemographic and Service Receipt Inventory (CSSRI). Indirect costs will be calculated based on the human capital approach. from baseline to 6 months and 12 and 24 months after baseline
Secondary cost effectiveness: health effects quality-adjusted life years (QALYs) will be calculated based on utilities derived from the EQ-5D-5L questionnaire from baseline to 6 months and 12 and 24 months after baseline
Secondary cost effectiveness: incremental cost-effectiveness incremental cost-effectiveness ratios (ICER) will be calculated from baseline to 6 months and 12 and 24 months after baseline
Secondary cost effectiveness: acceptability Cost-effectiveness acceptability curves (CEAC) will be calculated. from baseline to 6 months and 12 and 24 months after baseline
See also
  Status Clinical Trial Phase
Recruiting NCT04788004 - Long-term Recovery: Longitudinal Study of Neuro-behavioral Markers of Recovery and Precipitants of Relapse
Recruiting NCT05684094 - Mechanisms of Risky Alcohol Use in Young Adults: Linking Sleep to Reward- and Stress-Related Brain Function N/A
Completed NCT03406039 - Testing the Efficacy of an Online Integrated Treatment for Comorbid Alcohol Misuse and Emotional Problems N/A
Completed NCT03573167 - Mobile Phone-Based Motivational Interviewing in Kenya N/A
Completed NCT04817410 - ED Initiated Oral Naltrexone for AUD Phase 1
Active, not recruiting NCT04267692 - Harm Reduction Talking Circles for American Indians and Alaska Natives With Alcohol Use Disorders N/A
Completed NCT03872128 - The Role of Neuroactive Steroids in Stress, Alcohol Craving and Alcohol Use in Alcohol Use Disorders Phase 1
Completed NCT02989662 - INIA Stress and Chronic Alcohol Interactions: Glucocorticoid Antagonists in Heavy Drinkers Phase 1/Phase 2
Recruiting NCT06030154 - Amplification of Positivity for Alcohol Use N/A
Active, not recruiting NCT05419128 - Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19 N/A
Completed NCT04564807 - Testing an Online Insomnia Intervention N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT04203966 - Mental Health and Well-being of People Who Seek Help From Their Member of Parliament
Recruiting NCT05861843 - Craving Assessment in Patients With Alcohol Use Disorder Using Virtual Reality Exposure
Terminated NCT04404712 - FAAH Availability in Psychiatric Disorders: A PET Study Early Phase 1
Enrolling by invitation NCT04128761 - Decreasing the Temporal Window in Individuals With Alcohol Use Disorder N/A
Not yet recruiting NCT06444243 - Psilocybin-assisted Therapy for Alcohol Use Disorder Phase 2
Not yet recruiting NCT06163651 - Evaluating a One-Year Version of the Parent-Child Assistance Program N/A
Not yet recruiting NCT06337721 - Preventing Alcohol Use Disorders and Alcohol-Related Harms in Pacific Islander Young Adults N/A
Enrolling by invitation NCT02544581 - Preliminary Analysis of the Soberlink Alcohol Breath Analyzer System's (SABA) Clinical Utility During Aftercare N/A